The HI-PEITHO Trial: Intermediate Risk PE Unpacked

Show notes

This episode breaks down the landmark HI-PEITHO trial (NEJM, March 2026), a multicenter randomized controlled trial of 544 patients that finally brings clarity to the category of intermediate-risk PE.

• The Inclusion Criteria: HI-PEITHO mandated a strict "intermediate-high" entry bar: RV:LV ratio > 1.0 plus dual objective signs of distress (e.g., HR > 100, BP < 110). It isolates the cohort most likely to crash.
• The 7-Hour Rapid Protocol: We discuss the operational shift away from the legacy 24-hour ICU drip. The trial utilized a concentrated, bilateral 7-hour infusion of ~17mg Alteplase via the EkoSonic system.
• 61% Risk Reduction: The headline result: US-CDT achieved a massive relative risk reduction in the primary composite endpoint (cardio-respiratory collapse or decompensation), with an event rate of 4.0% vs. 10.3% in the heparin-only arm.
• The Safety Holy Grail: In a major win for the "local low-dose" strategy, there were 0% intracranial hemorrhages (ICH) in both groups. Major bleeding rates were statistically insignificant (P = 0.64), validating the safety of this sub-20mg protocol.
• Mechanical Thrombectomy Question: While HI-PEITHO establishes a modern benchmark for lytics, it does not address the rise of large-bore mechanical thrombectomy. It sets the safety and stabilization bar that future MT trials must now cross.

Tune in to learn about the March 2026 data!